FCRL3 and neoplasm: In addition, high expression of TIGIT or FCRL3 has been shown to correlate with CD26 loss and a high tumor burden [78,122], and clinical remission coincided with the disappearance of CD4+CD26− T cells expressing FCRL3 [78], suggesting that the immunoregulatory phenotype of SS T cells plays an active role in disease.